2Y3 Stock Chart & Stats
€4.39
--
Market closed
€4.39
--
Day’s Range― - ―
52-Week Range€4.39 - €5.31
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€11.26M
Enterprise Value€5.19
Total Cash (Recent Filing)€24.67M
Total Debt (Recent Filing)€17.01M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Jul 30, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.80
Shares Outstanding11,475,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.50Price Target Upside-20.37% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.03
Revenue Forecast (FY)€28.25M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthGrowth in consumables demonstrates stronger installed-base utilization under an instrument-led consumables model. Recurring kit/flow cell pull-through increases predictable revenue, improves lifetime customer value, and supports margin expansion as systems scale, creating durable commercial leverage.
Improving Gross MarginA near-term step-up in gross margin reflects a favorable revenue mix toward higher-margin consumables and operational efficiencies. Sustained margin improvement reduces reliance on new funding, accelerates path to break-even at scale, and increases cash available for commercial and R&D investment over time.
Reimbursement & Clinical Adoption CatalystsMaterial CPT reimbursement increases materially improve test economics for clinical labs and payor coverage feasibility. Better reimbursement lowers adoption barriers, supports repeat testing volumes, and can structurally expand the addressable clinical market for OGM over multiple years.
Bears Say
Negative Cash Flow And Limited RunwayPersistent negative operating and free cash flow means the company remains dependent on external capital unless it achieves sustained breakeven. With Q1 liquidity around $24.7M and runway into 2027, cash constraints could curtail commercialization, delay scale investments, or force dilutive financings if margins or growth stall.
Revenue Decline And Lumpy Software SalesA multiyear pattern of declining TTM revenue plus dependence on episodic, large software deals creates revenue volatility and undermines predictable consumables pull-through. This hampers planning, makes operating leverage fragile, and raises execution risk until recurring revenue components dominate total sales.
Leadership Turnover And Execution RiskRapid executive changes (CEO removal, interim CEO, CMO exit) increase execution and continuity risk during a critical commercialization and clinical validation phase. Leadership shifts can slow strategic decisions, affect fundraising confidence, and complicate relationships with clinical partners and regulators.
BioNano Genomics News
2Y3 FAQ
What was Bionano Genomics’s price range in the past 12 months?
Bionano Genomics lowest stock price was €4.39 and its highest was €5.31 in the past 12 months.
What is Bionano Genomics’s market cap?
Bionano Genomics’s market cap is €11.26M.
When is Bionano Genomics’s upcoming earnings report date?
Bionano Genomics’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Bionano Genomics’s earnings last quarter?
Bionano Genomics released its earnings results on May 13, 2026. The company reported -€0.666 earnings per share for the quarter, beating the consensus estimate of -€0.771 by €0.105.
Is Bionano Genomics overvalued?
According to Wall Street analysts Bionano Genomics’s price is currently Overvalued.
Does Bionano Genomics pay dividends?
Bionano Genomics does not currently pay dividends.
What is Bionano Genomics’s EPS estimate?
Bionano Genomics’s EPS estimate is -0.6.
How many shares outstanding does Bionano Genomics have?
Bionano Genomics has 11,475,000 shares outstanding.
What happened to Bionano Genomics’s price movement after its last earnings report?
Bionano Genomics reported an EPS of -€0.666 in its last earnings report, beating expectations of -€0.771. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bionano Genomics?
Currently, no hedge funds are holding shares in DE:2Y3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bionano Genomics
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
2Y3 Stock 12 Month Forecast
Average Price Target
€3.50
▼(-20.37% Downside)